Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

The conversation discusses the absorption and effectiveness of PG-free versus PG versions of RU58841, with some users believing PG improves efficacy while others see no difference. Concerns about RU58841's potential side effects on the endocrine system are also mentioned, with one user considering switching to pyrilutamide.

PP405 is a new drug in Phase 2 trials for hair loss, generating cautious optimism among users. Some users are currently using finasteride and experiencing side effects, while others are skeptical about unapproved products being sold.

An 18-year-old experiencing hair loss and seborrheic dermatitis has tried finasteride, dutasteride, and various shampoos without success. They are considering anti-androgens like RU58841 and KX-826 for oil control and dandruff reduction.

Clascoterone's European release is expected in Q4 2026, with FDA approval anticipated by mid-2027. The discussion includes questions about the approval timeline and potential acceleration due to unmet needs.

The conversation is about sourcing gray market compounds, gt20029 and pp405, for hair loss treatment. The user is interested in these compounds despite their unproven status and potential risks.

Nicotine use appears to increase hair shedding, with users noticing more hair loss when using nicotine and less when abstaining. Some users plan to quit nicotine and start treatments like finasteride and oral minoxidil to improve hair quality.

The conversation is about hair loss treatments, specifically Pyrludimide (KX-826) and Breezula (clascoterone), with the user unable to tolerate finasteride and dutasteride. The user plans to use these treatments alongside minoxidil, considering the efficacy and availability of each option.

Severe scalp itching and hair loss, possibly linked to seborrheic dermatitis, are discussed, with treatments like Dutasteride, Finasteride, and various shampoos mentioned. Some users find relief from itching with DHT blockers like Finasteride, while others suggest consulting multiple dermatologists for accurate diagnosis.

The user experienced severe side effects from finasteride, including anxiety and libido issues, and is currently using topical minoxidil and microneedling. They are considering trying dutasteride but are concerned about potential side effects.

PP405 was ineffective for hair growth as some follicles were already active before treatment, raising doubts about its efficacy. Users discussed other hair loss treatments like Minoxidil, finasteride, and RU58841, expressing skepticism and hope for future solutions.

Relaxation may promote hair growth by reducing corticosterone, which affects hair follicle stem cells. Corticosteroids are used for alopecia areata, but their long-term use for androgenic alopecia is uncertain.

The conversation discusses the potential updates on the pp405 trial for hair loss, with completion expected by December 2025. Participants express skepticism about new treatments, suggesting continued use of finasteride, while others hope for innovative solutions beyond current medications.

The discussion revolves around the need for future oral DHT blockers for hair loss treatment that don't have the side effects of current options like Finasteride and Dutasteride. One user suggests that the future of hair loss treatment will likely be topical anti-androgens, as they can target hair follicles without affecting the entire system.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

GT20029 is discussed as a potential treatment for androgenetic hair loss by targeting androgen receptors, unlike finasteride which reduces DHT broadly. Concerns include its effectiveness, genetic variations in androgen receptors, and availability, with some skepticism about its potential as a true alternative.

Balding scalps have more androgen receptors, leading to increased TGF-beta, which causes blood vessel loss and hair follicle miniaturization. Blocking androgen signaling and TGF-beta may help prevent hair loss.

The conversation discusses hair loss and its potential link to caffeine consumption, with the original poster experiencing increased shedding after consuming more coffee. They mention being a non-responder to finasteride and plan to reduce coffee intake, while others suggest various factors like stress, physical exertion, and medication changes could also contribute to hair loss.

PP405 is expected to be on the market between 2027 and 2030, with phase 3 trials starting in 2026. There is skepticism about its fast-tracking due to its cosmetic nature, and it may appear on the gray market sooner.

Upcoming hair loss treatments for those who can't tolerate DHT blockers, focusing on Minoxidil, microneedling, and ketoconazole. Promising treatments include GT20029, PP405, KX-826, and RU58841, though RU58841 may not be safe.

The user is experiencing intense hair shedding all over the scalp after applying pyrilutamide to the hairline and taking oral castor oil. They are also using topical finasteride and latanoprost, but are unsure which treatment is causing the shedding.

Finasteride can cause side effects like erectile dysfunction and decreased libido, possibly due to increased estradiol from testosterone aromatization, especially in those with higher body fat. Side effects vary widely and may also be influenced by genetic factors or neurosteroid inhibition.

Increased coffee intake might be linked to hair shedding, but the cause is unclear. The user is on finasteride and has increased water intake, possibly affecting electrolyte balance.

Switching from propylene glycol to glycerin in topical finasteride may reduce systemic absorption and side effects while maintaining local scalp DHT suppression. Concerns exist about glycerin's ability to deliver the full dose to hair follicles.

The user is experiencing side effects from oral minoxidil and is considering switching to a topical solution or reducing the dose. They are also using dutasteride and are seeking advice on managing side effects and treatment alternatives.

Minoxidil use may worsen seborrheic dermatitis, causing itching and dandruff. Users consider stopping minoxidil or switching to foam to improve scalp condition.

Alfatradiol is discussed as a hair loss treatment with minimal side effects, but its effectiveness is debated, and it's not widely known or available outside Germany. Some users report side effects like gyno and ball ache, while others find it effective in stopping shedding and itching.

Oral minoxidil can cause facial bloating, leading to a puffy appearance. Some users report improvement after stopping the medication.

Liquid Minoxidil caused headaches and eye irritation, possibly due to propylene glycol. Switching to foam may reduce side effects.

A natural compound called C3A from Aronia Chokeberry can help prevent hair loss by counteracting the effects of DHT. The user has been taking 50 grams of dried organic Aronia Chokeberry daily for 30 days and will update with photos in 60 days.

Taking 2.5mg of dutasteride daily can cause feelings of low energy, ambition, and motivation, likely due to hormonal imbalances. Many users suggest lowering the dose to 0.5mg to alleviate these side effects.